Add To Watchlist
Share URL
About The Company
CEO
Dr. Reshma Kewalramani FASN, M.D.
Market Cap
103.52 Billion USD
Sector
Healthcare
Website
https://www.vrtx.comLast Update
2/22/2024, 12:00:00 PM
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
Read More
Overview
Value
24
Growth
78
Health
71
Management
66
Analyst Opinion
91
Total
66
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Earnings growth has slowed down recently
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Price-to-earnings ratio of 30.4 is higher than the market average (19.6x)
- Dividend could be at risk
Market Peers
VRTX
Key Figures
PE Ratio (TTM)
30.41
Margin Of Safety (DCF)
-20.45%
Revenue Growth (5 Year Average)
17.90%
Ratings Consensus
Strong Buy
Share Buybacks
-0.58%
Dividend Yeild (TTM)
0.07%
Valuation
Value Score
24
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 3164898171.7 USD ✔
Current Price: 427 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
30.41x
Free Cashflow Yeild
2.97%
PE/Earnings Growth
0.71
Price/Book
6.27x
Growth
Growth Score
78
- ✔ 5 Year Average Revenue growth of 17.90% is higher than the market average (10.97%)
- ✔ 5 Year Average Earnings growth of 22.64% is higher than the market average (14.48%)
- ✔ 5 Year Average Cashflow growth of 24.57% is higher than the market average (12.35%)
- ✘ Revenue growth has slowed this year
- ✘ Earnings growth has slowed this year
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
17.90%
Earnings Growth
22.64%
Cashflow Growth
24.57%
Health
Health Score
71
Altman Z Score
15.14
Piostroski Score
3.00
Debt/Equity
0.06x
Current Assets/Liabilities
5.22x
Free Cashflow/Total Debt
4.84x
Debt/Capital
0.06x
Dividend
Secure Dividend Score
0
- ✔ Long term dividend payout ratio of 0.00% is considered good
- ✔ Payout ratio (TTM) of 2.04% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✘ Dividend yeild of 0.07% is less than the market average (1.85%)
- ✘ Very unsafe
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.07%
Dividend Growth
0.00%
Payout Ratio (Earnings)
2.04%
Payout Ratio (Cashflow)
2.26%
Management
Management Score
66
Average Buybacks/Dilution
-0.58%
Recent Buybacks/Dilution
0.86%
5 Year Price Volitility
20.84%
Return On Assets
18.46%
Return On Capital Employed
22.27%
Return On Equity
24.08%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
91
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Vertex Pharmaceuticals Incorporated
Currency
USD
Beta
0.510245
Vol Avg
1240337
Ceo
Dr. Reshma Kewalramani FASN, M.D.
Cik
0000875320
Cusip
92532F100
Exchange
NASDAQ Global Select
Full Time Employees
4800
Industry
Biotechnology
Sector
Healthcare
Ipo Date
1991-07-24
Address
50 Northern Avenue
City
Boston
State
MA
Country
US
Zip
02210
Phone
617 341 6100
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A